Bayer AG NA (BAYN STU) stock market data APIs
€27.4623
-0.13(-0.5%)
as of July 16, 2025
Try our APIs with
free plan!
Bayer AG NA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BAYN.SG.
Prev. Close
27.4623
Open
27.3349
High
27.5423
Low
27.3108
52 wk Range
18.3428-30.8683
Market Cap
45 791 M
EPS
2.49
Dividends (Yield)
0.0496
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bayer AG NA data using free add-ons & libraries
Get Bayer AG NA Fundamental Data
Bayer AG NA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: 2.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bayer AG NA News
New
World Bank adds Bayer, Hyatt and other CEOs to private sector initiative
By Andrea Shalal WASHINGTON (Reuters) -The World Bank on Wednesday added four top executives, including Bayer AG CEO Bill Anderson and Hyatt Hotels CEO Mark Hoplamazian, to an initiative working to a...
Farmers’ Favorite Weedkiller Nears Its End, Bayer Warns
Pharmaceutical and agriculture conglomerate Bayer said it could stop producing the world’s most popular weedkiller, unless it gets court protection against lawsuits blaming the herbicide for causing...
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor. The drug is now fully approved in the United States for adult ...
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation
The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic rece...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
